Drug Profile


Alternative Names: ABT-530

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie
  • Class Antivirals; Benzimidazoles; Carbamates; Fluorobenzenes; Piperidines; Pyrrolidines
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 19 Apr 2017 Interim efficacy data from a phase II trial in MAGELLAN-1 in Hepatitis C presented at the at the International Liver Congress 2017 (ILC-2017)
  • 13 Feb 2017 Drug interactions and adverse events data from a clinical trial in Healthy volunteers presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 13 Feb 2017 Abbvie initiates enrolment in a phase I trial in Healthy volunteers (Combination therapy) before February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top